Memorandum of Understanding Between the Food and Drug Administration and the State of Illinois, Emergency Management Agency, Bureau of Radiation Safety, 40380-40385 [05-13706]

Download as PDF 40380 Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [FDA 225–04–4005] Memorandum of Understanding Between the Food and Drug Administration and the State of Illinois, Emergency Management Agency, Bureau of Radiation Safety AGENCY: Food and Drug Administration, HHS. ACTION: Notice. VerDate jul<14>2003 19:23 Jul 12, 2005 Jkt 205001 SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between the Food and Drug Administration and the State of Illinois, through the Illinois Emergency Management Agency, to continue to conduct a State as certifiers program in Illinois under the Mammography Quality Standards Act as amended by the Mammography Quality Standards Reauthorization Act of 1998. DATES: The agreement became effective August 18, 2004. FOR FURTHER INFORMATION CONTACT: Joanne Choy, Center for Devices and PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 Radiological Health (HFZ–240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301–827– 2963. In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the Federal Register, the agency is publishing notice of this MOU. SUPPLEMENTARY INFORMATION: Dated: June 30, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. BILLING CODE 4160–01–S E:\FR\FM\13JYN1.SGM 13JYN1 VerDate jul<14>2003 17:40 Jul 12, 2005 Jkt 205001 PO 00000 Frm 00075 Fmt 4703 Sfmt 4725 E:\FR\FM\13JYN1.SGM 13JYN1 40381 EN13JY05.160</GPH> Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices VerDate jul<14>2003 Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices 17:40 Jul 12, 2005 Jkt 205001 PO 00000 Frm 00076 Fmt 4703 Sfmt 4725 E:\FR\FM\13JYN1.SGM 13JYN1 EN13JY05.161</GPH> 40382 VerDate jul<14>2003 17:40 Jul 12, 2005 Jkt 205001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4725 E:\FR\FM\13JYN1.SGM 13JYN1 40383 EN13JY05.162</GPH> Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices VerDate jul<14>2003 Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices 17:40 Jul 12, 2005 Jkt 205001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4725 E:\FR\FM\13JYN1.SGM 13JYN1 EN13JY05.163</GPH> 40384 [FR Doc. 05–13706 Filed 7–12–05; 8:45 am] BILLING CODE 4160–01–C DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers and Methods and Kits for Targeting National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 60/010,166, filed January 5, 1996, entitled ‘‘Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers VerDate jul<14>2003 17:40 Jul 12, 2005 Jkt 205001 And Methods And Kits For Targeting’’ [E–002–1996/0–US–01]; United States Patent No. 6,153,430, issued on November 28, 2000, entitled ‘‘Nucleic Acid Encoding Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers’’ [E–002–1996/0–US– 02]; United States Patent Application No. 09/684,599, filed October 5, 2000, entitled ‘‘Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers And Methods And Kits For Targeting’’ (E–002–1996/0–US–03); United States Patent No. 6,083,502, issued on July 4, 2000, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/1–US–02]; PCT Application No. PCT/US97/00224, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/1–PCT–01]; Australian Patent No. 703769, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/1–AU–03]; Canadian Patent No. 2241604, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 40385 Targeting It’’ [E–002–1996/1–CA–04]; Japanese Patent Application No. 9– 525355, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/ 1–JP–06]; European Patent No. 0871492, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/ 1–EP–05]; Switzerland Patent Application No. 0871492, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/1–CH–07]; German Patent No. 69726404.1, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ (E– 002–1996/1–DE–08); French Patent Application No. 0871492, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/1–FR–09]; Italian Patent No. 05503/BE/2004, January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E– 002–1996/1-–T–10]; Spanish Patent No. 0871492, filed January 3, 1997, entitled ‘‘Mesothelium Antigen And Methods And Kits For Targeting It’’ [E–002–1996/ 1–ES–11]; United Kingdom Patent No. E:\FR\FM\13JYN1.SGM 13JYN1 EN13JY05.164</GPH> Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices

Agencies

[Federal Register Volume 70, Number 133 (Wednesday, July 13, 2005)]
[Notices]
[Pages 40380-40385]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13706]



[[Page 40380]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA 225-04-4005]


Memorandum of Understanding Between the Food and Drug 
Administration and the State of Illinois, Emergency Management Agency, 
Bureau of Radiation Safety

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is providing notice of 
a memorandum of understanding (MOU) between the Food and Drug 
Administration and the State of Illinois, through the Illinois 
Emergency Management Agency, to continue to conduct a State as 
certifiers program in Illinois under the Mammography Quality Standards 
Act as amended by the Mammography Quality Standards Reauthorization Act 
of 1998.

DATES: The agreement became effective August 18, 2004.

FOR FURTHER INFORMATION CONTACT: Joanne Choy, Center for Devices and 
Radiological Health (HFZ-240), Food and Drug Administration, 1350 
Piccard Dr., Rockville, MD 20850, 301-827-2963.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which 
states that all written agreements and MOUs between FDA and others 
shall be published in the Federal Register, the agency is publishing 
notice of this MOU.

    Dated: June 30, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
BILLING CODE 4160-01-S

[[Page 40381]]

[GRAPHIC] [TIFF OMITTED] TN13JY05.160


[[Page 40382]]


[GRAPHIC] [TIFF OMITTED] TN13JY05.161


[[Page 40383]]


[GRAPHIC] [TIFF OMITTED] TN13JY05.162


[[Page 40384]]


[GRAPHIC] [TIFF OMITTED] TN13JY05.163


[[Page 40385]]


[GRAPHIC] [TIFF OMITTED] TN13JY05.164


[FR Doc. 05-13706 Filed 7-12-05; 8:45 am]
BILLING CODE 4160-01-C
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.